Bladder EpiCheck

DIAGNOSTIC_TEST4 trials

Sponsors

Nucleix Ltd.

Conditions

Bladder CancerCystoscopyHematuriaNMIBC SurveillanceNon Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial CarcinomaSuspicion of Bladder CancerUrothelial Carcinoma Bladder

Unknown Phase

Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma

CompletedNCT02647112

Nucleix Ltd.Bladder Cancer

Start: 2015-12-31End: 2020-12-31Updated: 2021-05-04

Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

CompletedNCT06020807

Nucleix Ltd.Non Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma

Start: 2019-09-05End: 2020-01-08Updated: 2023-09-07

Bladder EpiCheck European Haematuria Study

RecruitingNCT06818136

Nucleix Ltd.Cystoscopy, Hematuria, Urothelial Carcinoma Bladder +2

Start: 2025-06-20End: 2026-12-01Target: 800Updated: 2026-01-22

Bladder EpiCheck Product Development Study

RecruitingNCT07514143

Nucleix Ltd.NMIBC Surveillance, Suspicion of Bladder Cancer

Start: 2025-09-15End: 2026-12-01Target: 1000Updated: 2026-04-07

Related Papers

Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.

2019-02-0575 citations